OSR Health (OSRHW) Interest & Investment Income (2023 - 2026)
OSR Health (OSRHW) posted Interest & Investment Income of $17475.2 for Q1 2026, up 5.79% sequentially from $16519.0 in Q4 2025, and up 304.74% YoY from $4317.6 in Q1 2025.
OSR Health (OSRHW) Interest & Investment Income (2023 - 2026) Analysis & Trends
OSR Health has reported Interest & Investment Income for 4 years, with the latest figure at $17475.2 in Q1 2026.
- Quarterly Interest & Investment Income rose 304.74% year-over-year to $17475.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77040.2 (up 283.56% YoY) and the FY2025 annual result came in at $63883.0, up 200.0% from the prior year.
- Interest & Investment Income advanced to $17475.2 in Q1 2026 per OSRHW's latest filing, from $16519.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $928762.0 in Q4 2023 and troughed at $1442.0 in Q3 2024.
- A 4-year average of $221380.2 and a median of $17475.2 in 2026 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income sank 99.77% in 2024, then surged 1181.14% in 2025.
- Over 4 years, Interest & Investment Income stood at $928762.0 in 2023, then tumbled by 98.94% to $9846.0 in 2024, then soared by 67.77% to $16519.0 in 2025, then rose by 5.79% to $17475.2 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $17475.2, $16519.0, and $18474.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.12 Bn | 131.27 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.30 Bn | 77.31 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 62.84 Bn | 57.66 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 55.67 Bn | 50.53 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.43 Bn | 36.33 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 27.47 Bn | 9.08 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.03 Bn | 25.87 Bn | 358.27 Mn | 10.98 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | 1,501.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,475.21 |
| Dec 31, 2025 | 16,519.00 |
| Sep 30, 2025 | 18,474.00 |
| Jun 30, 2025 | 24,572.00 |
| Mar 31, 2025 | 4,317.60 |
| Dec 31, 2024 | 9,846.00 |
| Sep 30, 2024 | 1,442.00 |
| Jun 30, 2024 | 4,480.00 |
| Mar 31, 2024 | 5,526.00 |
| Dec 31, 2023 | 928,762.00 |
| Sep 30, 2023 | 618,499.00 |
| Jun 30, 2023 | 810,302.00 |
| Mar 31, 2023 | 417,728.00 |